How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion [Yahoo! Finance]
PTC Therapeutics, Inc. (PTCT)
Last ptc therapeutics, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ptcbio.com
Company Research
Source: Yahoo! Finance
Sarepta reported that the patient's death was due to acute liver failure, a known but rare risk associated with the use of Elevidys. This marks the first reported fatality linked to the gene therapy. Despite the incident, the company maintained its stance on the therapy's positive benefit-risk profile, emphasizing that more than 800 patients have received Elevidys to date. Additionally, Sarepta noted that the patient had a recent CMV infection, which might have contributed to the adverse outcome, as CMV is known to cause liver damage. This announcement has raised negative sentiments around the stock — investors are concerned that Elevidys sales could be negatively impacted as the event could slow overall market adoption of the therapy
Read more
Impact Snapshot
Event Time:
PTCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTCT alerts
High impacting PTC Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTCT
News
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in EuropePR Newswire
- PTC Therapeutics Presents New Sepiapterin Data from Ongoing StudiesPR Newswire
- PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at JPMorgan Chase & Co. from $72.00 to $78.00. They now have an "overweight" rating on the stock.MarketBeat
- PTC Therapeutics, Inc. (NASDAQ: PTCT) was upgraded by analysts at Bank of America Co. from an "underperform" rating to a "neutral" rating. They now have a $55.00 price target on the stock, up previously from $41.00.MarketBeat
PTCT
Earnings
- 2/27/25 - Beat
PTCT
Sec Filings
- 3/28/25 - Form 8-K
- 3/18/25 - Form 4
- 3/17/25 - Form 4
- PTCT's page on the SEC website